A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis

Anna Rita Giardina (1) , Angelo Ferrante (1) , Francesco Ciccia (1) , Rosalia Impastato (1) , Maria Concetta Miceli (1) , Alfonso Principato (1) , Giovanni Triolo (1)

1 Division of Rheumatology, Department of Internal Medicine

The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, corticosteroids, and disease modifying antirheumatic drugs in quite a number of patients. Tumor necrosis factor inhibitors have demonstrated to be of value in reducing AS disease activity in clinical trials. The efficacy and safety of both etanercept and infliximab in patients with ankylosing spondylitis were compared in a 2-year open label randomised study. Our results are consistent with a significant more rapid clinical improvement in the infliximab treated group. Treatment with both etanercept and infliximab at the end of the study was effective, safe, and well tolerated.

Mots clés: Ankylosing spondylitis; Etanercept; Infliximab

Anna Rita Giardina, Angelo Ferrante, Francesco Ciccia, Rosalia Impastato, Maria Concetta Miceli, et al.. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatology International, 2009, 30 (11), pp.1437-1440. ⟨10.1007/s00296-009-1157-3⟩. ⟨hal-00562259⟩